Led · Series A · Sep 2024

AmpUp provides a smart EV charging platform and energy management solutions aimed at simplifying charging and balancing energy usage. The company operates a network of thousands of EV charging stations deployed for customers across North America, including JLL, CBRE, Domino’s Pizza, Goodyear, Under Armour, and Hilton. Led by CEO Tom Sun, AmpUp focuses on technology that supports a cleaner, smarter grid through intelligent charging and energy management. With the completion of its Series A, the company plans to accelerate market expansion and continue innovating within the EV charging sector. The round reinforces AmpUp's position in the commercial charging market and supports its ongoing product and go-to-market initiatives. AmpUp, founded in 2018 and based in Santa Clara, California, provides comprehensive EV charging services in North America. The company operates a platform and services for electric-vehicle charging deployment and management. In December last year Hyundai Motor acquired a minority equity stake in AmpUp, reflecting strategic investor interest. AmpUp previously received an investment from Hyundai's Cradle team in 2020 (amount undisclosed). Beyond those disclosed investments, the article provides no revenue, user, or other operating metrics. No explicit future product plans for AmpUp were detailed in the article. AmpUp is a Santa Clara, CA-based provider of an electric vehicle (EV) charging operating system. Its platform manages a network of Level 2 and DC Fast chargers deployed across North America for customers including JLL, CBRE, Domino’s Pizza, Goodyear, Under Armour, and Hilton. The company reports its network represents over 30% of all networked Level 2 charging stations in Connecticut and over 94% of all private chargers in the state. AmpUp also reports a 96.4% charge session success rate and nearly 100% system uptime across its integrated network. Led by CEO Tom Sun, AmpUp plans to deepen its presence in Connecticut by opening a new office in East Hartford in early 2024. In December 2023 the company received a $1.7M grant from the State of Connecticut’s Public Utility Regulatory Authority to support EV charging demand flexibility. AmpUp offers a proprietary EV charging operating system that centralizes management of multiple charge stations and locations, simplifies charge scheduling, and optimizes energy use. The platform provides increased visibility into key charging metrics and infrastructure control for organizations and drivers. AmpUp's software has been deployed across North America and Europe and serves customers including JLL, CBRE, Cushman & Wakefield, Citizens Bank, Hilton Garden Inn, and Holiday Inn. The company plans to accelerate fleet electrification by making smart charging solutions easier to scale and implement. A strategic investment and collaboration with Holman is intended to integrate AmpUp's charging data with Holman's vehicle operating data to reduce data fragmentation, mitigate fraud, and eliminate visibility blind spots for fleet operators. AmpUp is a Cupertino, CA-based software company and network provider that builds EV charging solutions for drivers, hosts and fleets. Its platform enables businesses and property owners to efficiently manage multiple charge stations and locations from a single interface. AmpUp operates across North America, including all 50 U.S. states, Canada, Mexico and Puerto Rico. The company's network and software have been deployed for customers such as JLL, CBRE, Cushman & Wakefield, Hilton Garden Inn and Holiday Inn. The business is led by CEO and co-founder Thomas Sun and combines network services with charging management software. The article does not disclose revenue, user counts, or other financial metrics.

Participated · Seed · Jun 2024

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s biology via its SYNT™ (SYNthetic Tissue-lining) platform. The SYNT platform delivers a transient polydopamine polymer coating in the small intestine to control nutrient uptake, sustain gut-restricted enzymes, and increase oral drug absorption for up to 24 hours. The company’s lead program, SYNT-101, is being developed as a once-daily pill for obesity and has shown preclinical weight-loss and muscle-preservation data as well as early human evidence of nutrient redirection, satiety-hormone modulation, and favorable safety. Syntis is also advancing SYNT-202, a first-in-class oral enzyme therapy for the rare pediatric disorder homocystinuria, and plans Phase 1 studies for both programs. Data from over 100 preclinical pig studies conducted by MIT and Syntis indicate SYNT can block glucose, improve enzyme activity, and increase oral drug bioavailability. The company is headquartered in Boston, MA. Syntis Bio is advancing a portfolio of oral therapies engineered to exploit the small intestine’s biology for metabolic control, digestion and drug absorption. Its lead program, SYNT-101, is a once-daily pill that transiently blocks nutrient absorption in the duodenum to mimic gastric bypass; a formulation is in human trials with a full data readout expected by the end of 2024 and plans to use those data to support an IND filing with the FDA in 2025. The company’s SYNT™ (SYNthetic Tissue-lining) platform delivers a transient polydopamine coating to the duodenum that persists up to 24 hours and, in more than 100 preclinical pig studies, has demonstrated up to 70% glucose blocking, 20x improved enzyme activity, and 4–10x increased oral drug bioavailability. In April 2024 Syntis acquired engineered enzyme programs from Codexis and is developing SYNT-202 for homocystinuria and SYNT-203 for maple syrup urine disease; both completed non-human primate studies and an IND for one candidate is anticipated in 2025. The company is also developing next-generation formulations and discovery-stage programs targeting pancreatic insufficiency and peptic ulcers. Syntis is headquartered in Boston and has raised $15.5 million to date from life-sciences and strategic investors.

Participated · Series A · Feb 2024

Valid8’s Verified Financial Intelligence platform automates extraction of source documents (bank statements including Bitcoin, brokerage statements, checks and deposit slips), performs quality assurance, reconciles and traces flows of funds, and generates visualizations and automated evidentiary reports. The product includes AI-powered bank statement extraction, automated transfer and cash-journal matching, multicurrency support (166 currencies, including Bitcoin) with daily ECB exchange rates, AI categorization, and chain-of-custody linkage of every transaction to source documents. The company says the platform delivers courtroom-ready evidence in hours instead of weeks or months and is used by accounting firms, law firms and government agencies. Valid8 completed TechStars in 2017, closed a seed round in 2021 and closed an $8.5 million Series A in November 2023. The company reports it has doubled revenue each year since 2019 and has resolved more than 20,000 cases, supports over 1,800 users, and has verified more than 400 million transactions. Valid8 plans to extend the platform into additional use cases including transaction advisory (M&A diligence) and financial statement audits and to maintain leadership in complex fraud investigations and crypto bankruptcies. The company intends to use recent funding to support engineering and go-to-market teams based at its Boulder, Colorado headquarters.

Participated · Series A · Sep 2023

DetraPel develops and manufactures PFAS-free, fluorine-free and bio-based protective coatings using patented chemistries and a platform for blending immiscible particles into water-based systems. Its technology produces barrier coatings at scale that preserve recyclability, repulpability and compostability. The company serves industries including paper & paperboard packaging, textiles and healthcare, and counts large paper suppliers and consumer packaged goods companies among its industrial customers. DetraPel recently rebranded its industrial arm as Impermea Materials and its consumer operations as ProofPlus and plans to use new funding to build market traction for those brands. Led by Founder and CEO David Zamarin, the company emphasizes sustainable, scalable alternatives to PFAS-containing coatings. DetraPel is based in Boston, MA.

Participated · Series A · Jun 2023

Mend is a Long Island City-based health-tech startup that offers a combined platform of high-quality nutritional supplements and technology-enabled remote monitoring tools aimed at improving patient outcomes in concierge medicine. Its products allow users to proactively track and enhance their health while receiving personalized dietary support. The company positions itself at the intersection of nutrition and digital health, targeting partnerships with surgical practices to embed its offerings in post-operative and long-term care regimes. Following its recent capital influx, Mend plans to broaden its supplement portfolio and scale its telehealth infrastructure. The leadership also intends to deepen integrations with clinical partners to capture a larger share of the growing personalized wellness market. The Series A financing underscores strong investor confidence in the firm’s ability to innovate within the nutrition and remote-care sectors. No revenue or user metrics were disclosed in the article, but the new funds provide runway to accelerate product development and market expansion.